Scientific technologies leader Thermo Fisher has announced a double development in research and innovation capabilities in the Asia-Pacific region, with a Memorandum of Understanding (MoU) agreed in Indonesia and a new biomedical facility opened in Singapore.
Thermo Fisher Scientific announced it had opened the new sterile drug facility in Singapore on 19th May. The facility will better enable customers to deliver new medicines and vaccines in the Asia-Pacific market.
It also marks a significant milestone and investment in pandemic preparedness for Singapore, which is fast emerging as a biomedical hub in the Asia-Pacific region.
Established with assistance from the Singapore Economic Development Board (EDB), in alignment with the government’s investment in preparedness for future health emergencies, the current Good Manufacturing Practices (cGMP) facility will provide rapid vaccine fill-finish capabilities along with Thermo Fisher’s end-to-end pharmaceutical development and manufacturing services.
... to continue reading you must be subscribed
